Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
TK Kim, EN Vandsemb, RS Herbst… - Nature Reviews Drug …, 2022 - nature.com
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
Programmed death ligand 1 signals in cancer cells
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
Revisiting the PD-1 pathway
Programmed Death-1 (PD-1; CD279) is an inhibitory receptor induced in activated T cells.
PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also …
PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also …
A paradigm shift in cancer immunotherapy: from enhancement to normalization
MF Sanmamed, L Chen - Cell, 2018 - cell.com
Harnessing an antitumor immune response has been a fundamental strategy in cancer
immunotherapy. For over a century, efforts have primarily focused on amplifying immune …
immunotherapy. For over a century, efforts have primarily focused on amplifying immune …
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1
as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive …
as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive …
Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond
L Ai, A Xu, J Xu - Regulation of Cancer Immune Checkpoints: Molecular …, 2020 - Springer
Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
Cancer stem cells as key drivers of tumour progression
AZ Ayob, TS Ramasamy - Journal of biomedical science, 2018 - Springer
Abstract Background Cancer stem cells (CSCs) are subpopulations of cancer cells sharing
similar characteristics as normal stem or progenitor cells such as self-renewal ability and …
similar characteristics as normal stem or progenitor cells such as self-renewal ability and …
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
[HTML][HTML] A snapshot of the PD-1/PD-L1 pathway
Cancer cells can evade the attack from host immune systems via hijacking the regulatory
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …